Your browser doesn't support javascript.
loading
Impact of somatic and germline mutations on the outcome of systemic mastocytosis.
Muñoz-González, Javier I; Jara-Acevedo, María; Alvarez-Twose, Iván; Merker, Jason D; Teodosio, Cristina; Hou, Yanli; Henriques, Ana; Roskin, Krishna M; Sanchez-Muñoz, Laura; Tsai, Albert G; Caldas, Carolina; Matito, Almudena; Sánchez-Gallego, J Ignacio; Mayado, Andrea; Dasilva-Freire, Noelia; Gotlib, Jason R; Escribano, Luis; Orfao, Alberto; García-Montero, Andrés C.
Afiliación
  • Muñoz-González JI; Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), CIBERONC, University of Salamanca, Salamanca, Spain.
  • Jara-Acevedo M; Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain.
  • Alvarez-Twose I; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.
  • Merker JD; Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain.
  • Teodosio C; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.
  • Hou Y; Sequencing Service (NUCLEUS), University of Salamanca, Salamanca, Spain.
  • Henriques A; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.
  • Roskin KM; Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Virgen del Valle Hospital, Toledo, Spain.
  • Sanchez-Muñoz L; Department of Pathology, Stanford University School of Medicine, Stanford, CA.
  • Tsai AG; Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands; and.
  • Caldas C; Department of Pathology, Stanford University School of Medicine, Stanford, CA.
  • Matito A; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.
  • Sánchez-Gallego JI; Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Virgen del Valle Hospital, Toledo, Spain.
  • Mayado A; Department of Pathology, Stanford University School of Medicine, Stanford, CA.
  • Dasilva-Freire N; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.
  • Gotlib JR; Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Virgen del Valle Hospital, Toledo, Spain.
  • Escribano L; Department of Pathology, Stanford University School of Medicine, Stanford, CA.
  • Orfao A; Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), CIBERONC, University of Salamanca, Salamanca, Spain.
  • García-Montero AC; Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain.
Blood Adv ; 2(21): 2814-2828, 2018 11 13.
Article en En | MEDLINE | ID: mdl-30373888
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas c-kit / Mastocitosis Sistémica Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged / Newborn Idioma: En Revista: Blood Adv Año: 2018 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas c-kit / Mastocitosis Sistémica Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged / Newborn Idioma: En Revista: Blood Adv Año: 2018 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos